Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GAIA-121-125 (D+)
- Development stage
- Preclinical
- Lead developer
- GAIA BioMedicine
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GAIA-121-125 (D+) is a preclinical-stage allogeneic cell therapy developed by GAIA BioMedicine. It utilizes the company's proprietary GAIA Antibody-Armed Allogeneic Platform (GAAAP), which involves arming peripheral blood mononuclear cell (PBMC)-derived NK-like cells with specific antibodies. This particular variant targets an undisclosed proprietary tumor-associated antigen referred to as "Antigen D+". The therapy is designed for intravenous administration to treat tumors expressing this antigen. Unlike traditional CAR-NK therapies, the GAAAP platform enhances tumor targeting through antibody-arming of the NK-like cells without genetic modification, leveraging the innate cytotoxic potential of the cells directed by the specificity of the armed antibody.
- Other names
- GAAAP antibody-armed NK-like cell (D+)
Beyond the preview
Go deeper on GAIA-121-125 (D+).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAIA-121-125 (D+).